Dimensional Fund Advisors LP Sells 119,788 Shares of ProAssurance Co. (NYSE:PRA)

Dimensional Fund Advisors LP decreased its holdings in shares of ProAssurance Co. (NYSE:PRA - Free Report) by 4.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,645,354 shares of the insurance provider's stock after selling 119,788 shares during the quarter. Dimensional Fund Advisors LP owned 5.19% of ProAssurance worth $32,327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Innealta Capital LLC purchased a new stake in ProAssurance in the 2nd quarter worth approximately $69,000. ProShare Advisors LLC purchased a new stake in shares of ProAssurance during the first quarter worth $132,000. Aull & Monroe Investment Management Corp acquired a new stake in ProAssurance during the first quarter valued at $178,000. Arizona State Retirement System grew its stake in ProAssurance by 8.1% in the second quarter. Arizona State Retirement System now owns 15,136 shares of the insurance provider's stock valued at $185,000 after purchasing an additional 1,128 shares in the last quarter. Finally, Aristides Capital LLC acquired a new position in ProAssurance in the 4th quarter worth about $256,000. 85.58% of the stock is owned by institutional investors and hedge funds.

ProAssurance Stock Performance

Shares of PRA stock traded down $0.14 during trading on Wednesday, reaching $15.01. The company had a trading volume of 247,433 shares, compared to its average volume of 290,103. The company has a market capitalization of $765.69 million, a PE ratio of -27.78 and a beta of 0.23. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.26 and a quick ratio of 0.26. The firm's 50 day simple moving average is $13.19 and its two-hundred day simple moving average is $13.12. ProAssurance Co. has a one year low of $10.76 and a one year high of $18.98.

ProAssurance (NYSE:PRA - Get Free Report) last announced its earnings results on Thursday, August 8th. The insurance provider reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.15. ProAssurance had a positive return on equity of 0.86% and a negative net margin of 2.00%. The firm had revenue of $290.30 million during the quarter, compared to the consensus estimate of $235.61 million. During the same quarter in the prior year, the company earned $0.16 EPS. The firm's revenue for the quarter was down .5% compared to the same quarter last year. Sell-side analysts forecast that ProAssurance Co. will post 0.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. JMP Securities reduced their price target on ProAssurance from $22.00 to $20.00 and set a "market outperform" rating for the company in a report on Wednesday, July 17th. Truist Financial dropped their price target on shares of ProAssurance from $16.00 to $14.00 and set a "hold" rating on the stock in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $16.33.

ProAssurance Company Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.